Trial record 1 of 1 for:
IPATHER - SOLTI 1507
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04253561 |
Recruitment Status :
Recruiting
First Posted : February 5, 2020
Last Update Posted : April 18, 2023
|
Sponsor:
SOLTI Breast Cancer Research Group
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | June 25, 2025 |
Estimated Study Completion Date : | August 25, 2025 |